Zimmer Biomet (ZBH) is a publicly traded Healthcare sector company. As of October 13, 2026, ZBH trades at $93.29 with a market cap of $17.00B and a P/E ratio of 25.32. ZBH moved +0.02% today. Year to date, ZBH is +2.50%; over the trailing twelve months it is -2.68%. Its 52-week range spans $79.12 to $114.44. Analyst consensus is buy with an average price target of $105.40. Rallies surfaces ZBH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for ZBH, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $93.29 |
| Market Cap | $17.00B |
| P/E Ratio | 25.32 |
| EPS | $3.56 |
| Dividend Yield | 0.24% |
| 52-Week High | $114.44 |
| 52-Week Low | $79.12 |
| Volume | 20.41K |
| Avg Volume | 0 |
| Revenue (TTM) | $8.23B |
| Net Income | $705.10M |
| Gross Margin | 69.70% |
18 analysts cover ZBH: 0 strong buy, 5 buy, 13 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $105.40.